Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Evaluation of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
2012-000586-20Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Primary endpoints: Primary antiviral efficacy and HBeAg seroconversion at Week 72. Started Sep 2012; status: terminated.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2012-000586-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000586-20.